Entrepreneurial Impact Amplified
Sangeeta Bhatia joins David Berry to explore cancer detection, liver cell therapies and how mentorship and entrepreneurship can help discoveries reach patients.
Conversations from Averin Capital
Averin Insights
The future of human health.
Averin Capital brings you inside conversations with the people shaping the future of human health. We explore the science opening new doors, the technologies changing what’s possible, and the work of building companies that bring those advances to patients.
Get new episodes by email ↓
The conversations
Read Perspectives →
Building The AI Powered Hospital
Michael Hasselberg of Nebraska Medicine joins David Berry on Averin Insights to discuss in-house AI, technology partnerships, and the hospital of the future.
Accelerating the Speed of Discovery
Andy Plump, President of Research & Development at Takeda, joins David Berry on Averin Insights to discuss how technology is changing drug discovery and development.
Betting on Breakthrough Biology
Christian Schubert, Vice President and Global Head of AbbVie Ventures, joins David Berry on Averin Insights to discuss early-stage biotech investing, working with founders, and where AI can make a meaningful difference in drug discovery.
Before Disease Decides
Thierry Bernard, CEO of QIAGEN, joins David Berry on Averin Insights to explore how diagnostics could help healthcare move from reacting to disease toward earlier detection and more personalized care.
Season 1
The Surgeon Is Still the System
With Rony Abovitz, Josh DeFonzo and Chris Morley
David Berry joins Rony Abovitz, Josh DeFonzo, and Chris Morley to explore how robotics, AI, and augmented reality are expanding surgeons’ capabilities. The discussion covers precision and consistency in care, the role of patient demand in adoption, and the next frontier of intervention at the cellular and tissue level.
The New Liquidity Landscape
With John Bishai, Paul Kinsella and Will Herrmann
David Berry joins John Bishai, Paul Kinsella, and Will Herrmann to explore exit strategies for healthcare and biotech companies. The discussion covers M&A trends, the outlook for IPOs in 2026, what buyers and investors look for, and how companies can position themselves for a successful exit.
Navigating Healthcare Regulation
With Peter Hutt, David Shulkin and Daniel Troy
David Berry joins Peter Hutt, David Shulkin, and Daniel Troy to explore how regulation, AI, and geopolitics are shaping healthcare and biotech. The discussion covers FDA enforcement trends, the challenges of evaluating AI-enabled products, and shifting global supply chains, and what they mean for innovators.
Activated Intelligence: AI’s Leap from Algorithm to Impact
With Andrew Hopkins, Jared Saul and Andrey Dobry
David Berry joins Andrew Hopkins, Jared Saul, and Andrey Dobry to explore how AI is transforming healthcare and biotech. The discussion covers AI-designed molecules, the role of data in scientific discovery, and the rise of autonomous systems reshaping drug development.
The Age of Longevity
With Nir Barzilai and Michael Ringel
David Berry joins longevity experts Nir Barzilai and Michael Ringel to explore the science of healthier, longer lives. The discussion covers lessons from centenarians, emerging therapies targeting aging, the promise of epigenetic reprogramming, and investment opportunities in longevity biotech.
Stay in the conversation.
Get new Averin Insights episodes and our latest writing on technology and human health in your inbox.